Methyl3-(morpholin-2-yl)propanoatehydrochloride | 2613382-92-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: Methyl3-(morpholin-2-yl)propanoatehydrochloride
• 英文别名: methyl 3-morpholin-2-ylpropanoate;hydrochloride
• CAS: 2613382-92-4
• 化学式: C8H16ClNO3
• 分子量: 209.67
• InChiKey: JMLMNAZUGZHSFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.09
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  52.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Dihydropyrimidine compounds and uses thereof in medicine
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US11142527B2

  公开（公告）日：2021-10-12

  A dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also, use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.

  一种二氢嘧啶化合物及其药物应用，尤其是用于治疗和预防 HBV 疾病的应用。具体地说，一种具有式（I）或（Ia）的化合物，或其对映体、非对映异构体、同分异构体、水合物、溶液或药学上可接受的盐，其中式中的变量如说明书中所定义。另外，将具有式（I）或（Ia）的化合物或其对映体、非对映异构体、同分异构体、水合物、溶液或药学上可接受的盐用作药物，特别是用于治疗和预防 HBV 疾病。
• DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE
  申请人：NlORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED

  公开号：US20200115381A1

  公开（公告）日：2020-04-16

  A dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also, use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.
• [EN] BTK INHIBITORS<br/>[FR] INHIBITEURS DE BTK
  申请人：MERCK SHARP & DOHME

  公开号：WO2016106625A1

  公开（公告）日：2016-07-07

  Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders is provided.